WO1999053905A1 - Comprimes a liberation prolongee a unites multiples - Google Patents
Comprimes a liberation prolongee a unites multiples Download PDFInfo
- Publication number
- WO1999053905A1 WO1999053905A1 PCT/JP1998/003537 JP9803537W WO9953905A1 WO 1999053905 A1 WO1999053905 A1 WO 1999053905A1 JP 9803537 W JP9803537 W JP 9803537W WO 9953905 A1 WO9953905 A1 WO 9953905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- granules
- water
- release
- active ingredient
- insoluble polymer
- Prior art date
Links
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 27
- 239000008187 granular material Substances 0.000 claims abstract description 120
- 239000011159 matrix material Substances 0.000 claims abstract description 49
- 239000004480 active ingredient Substances 0.000 claims abstract description 44
- 229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 229920001249 ethyl cellulose Polymers 0.000 claims description 28
- 239000001856 Ethyl cellulose Substances 0.000 claims description 27
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 27
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 27
- 239000007771 core particle Substances 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000013270 controlled release Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 abstract description 49
- 238000010828 elution Methods 0.000 abstract description 21
- 238000007906 compression Methods 0.000 abstract description 3
- 230000006835 compression Effects 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 description 28
- 239000007931 coated granule Substances 0.000 description 26
- 238000000576 coating method Methods 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 23
- 238000013268 sustained release Methods 0.000 description 22
- 239000012730 sustained-release form Substances 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000007922 dissolution test Methods 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 238000000465 moulding Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- -1 carboxymethylethyl Chemical group 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 4
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 1
- 101100120289 Drosophila melanogaster Flo1 gene Proteins 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229930185735 nosporin Natural products 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960004767 proxyphylline Drugs 0.000 description 1
- 125000002327 selenol group Chemical class [H][Se]* 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002328154A CA2328154A1 (en) | 1998-04-17 | 1998-08-07 | Multiple-unit sustained release tablets |
EP98936707A EP1072257A1 (en) | 1998-04-17 | 1998-08-07 | Multiple-unit sustained release tablets |
US09/673,398 US6558700B1 (en) | 1998-04-17 | 1998-08-07 | Multiple-unit sustained release tablets |
AU85617/98A AU746084B2 (en) | 1998-04-17 | 1998-08-07 | Multiple-unit sustained release tablets |
KR1020007011272A KR20010034770A (ko) | 1998-04-17 | 1998-08-07 | 멀티플 유닛 타입 서방성 정제 |
HK01106865A HK1036220A1 (en) | 1998-04-17 | 2001-09-28 | Multiple-unit sustained release tablets. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/107349 | 1998-04-17 | ||
JP10734998 | 1998-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999053905A1 true WO1999053905A1 (fr) | 1999-10-28 |
Family
ID=14456811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003537 WO1999053905A1 (fr) | 1998-04-17 | 1998-08-07 | Comprimes a liberation prolongee a unites multiples |
Country Status (8)
Country | Link |
---|---|
US (1) | US6558700B1 (ja) |
EP (1) | EP1072257A1 (ja) |
KR (1) | KR20010034770A (ja) |
CN (1) | CN1148171C (ja) |
AU (1) | AU746084B2 (ja) |
CA (1) | CA2328154A1 (ja) |
HK (1) | HK1036220A1 (ja) |
WO (1) | WO1999053905A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118017A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 安定化組成物 |
US8124780B2 (en) | 2005-04-15 | 2012-02-28 | Eisai R&D Management Co., Ltd. | Benzimidazole compound |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
ITMI20031096A1 (it) * | 2003-05-30 | 2004-11-30 | Eurand Spa | Microcapsule per coacervazione contenenti farmaco incorporato nel polimero di rivestimento |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2584957C (en) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
US20070082050A1 (en) * | 2005-05-31 | 2007-04-12 | Cherukuri S R | Modified release formulations of antihypertensive drugs |
EP2012756A4 (en) * | 2006-04-20 | 2013-01-23 | Inventia Healthcare Private Ltd | MULTI-UNIT COMPOSITIONS |
US20090196934A1 (en) * | 2006-07-26 | 2009-08-06 | Asahi Kasei Chemicals Corporation | Spherical elementary granule and method for production thereof |
WO2011067667A2 (en) | 2009-12-02 | 2011-06-09 | Eurand Pharmaceuticals Limited | Fexofenadine microcapsules and compositions containing them |
CN102091053B (zh) * | 2009-12-14 | 2017-02-08 | 常州善美药物研究开发中心有限公司 | 一种颗粒组合控释片 |
CN101716155B (zh) * | 2010-01-21 | 2011-10-05 | 中山大学 | 一种微丸片的制备方法 |
WO2011127235A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
EP2425826A1 (en) * | 2010-09-01 | 2012-03-07 | Disphar International B.V. | Mesalazine tablet having improved dissolution |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753365A (ja) * | 1993-07-22 | 1995-02-28 | Lab Farmaceut Ct Srl | γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物 |
JPH0753361A (ja) * | 1993-05-10 | 1995-02-28 | Euro Celtique Sa | 放出が調整された調合物、経口投与形態及びその製造方法 |
WO1995010264A1 (fr) * | 1993-10-12 | 1995-04-20 | Tokyo Tanabe Company Limited | Tablette contenant des granules entero-solubles |
JPH07316042A (ja) * | 1994-05-24 | 1995-12-05 | Shionogi & Co Ltd | マルチプルユニット型錠剤 |
JPH0840905A (ja) * | 1994-03-14 | 1996-02-13 | Euro Celtique Sa | 医薬製剤 |
JPH08175983A (ja) * | 1994-12-19 | 1996-07-09 | Taisho Yakuhin Kogyo Kk | ジクロフェナクナトリウム持続性製剤およびその製法 |
JPH09169645A (ja) * | 1995-12-20 | 1997-06-30 | Taisho Yakuhin Kogyo Kk | イブジラスト含有持続性製剤およびその製法 |
JPH10218761A (ja) * | 1997-02-07 | 1998-08-18 | Taisho Pharmaceut Co Ltd | マルチプルユニットタイプ徐放性錠剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5246714A (en) * | 1985-10-11 | 1993-09-21 | Aktiebolaget Hassle | Drug preparation |
US4710384A (en) | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
US5624683A (en) * | 1986-08-06 | 1997-04-29 | Eisai Co., Ltd. | Sustained-release multi-granule tablet |
JPH0817983A (ja) | 1994-06-29 | 1996-01-19 | Nec Kansai Ltd | 半田めっき装置 |
-
1998
- 1998-08-07 AU AU85617/98A patent/AU746084B2/en not_active Ceased
- 1998-08-07 US US09/673,398 patent/US6558700B1/en not_active Expired - Fee Related
- 1998-08-07 CN CNB988140594A patent/CN1148171C/zh not_active Expired - Fee Related
- 1998-08-07 KR KR1020007011272A patent/KR20010034770A/ko not_active Application Discontinuation
- 1998-08-07 CA CA002328154A patent/CA2328154A1/en not_active Abandoned
- 1998-08-07 EP EP98936707A patent/EP1072257A1/en not_active Withdrawn
- 1998-08-07 WO PCT/JP1998/003537 patent/WO1999053905A1/ja not_active Application Discontinuation
-
2001
- 2001-09-28 HK HK01106865A patent/HK1036220A1/xx not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753361A (ja) * | 1993-05-10 | 1995-02-28 | Euro Celtique Sa | 放出が調整された調合物、経口投与形態及びその製造方法 |
JPH0753365A (ja) * | 1993-07-22 | 1995-02-28 | Lab Farmaceut Ct Srl | γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物 |
WO1995010264A1 (fr) * | 1993-10-12 | 1995-04-20 | Tokyo Tanabe Company Limited | Tablette contenant des granules entero-solubles |
JPH0840905A (ja) * | 1994-03-14 | 1996-02-13 | Euro Celtique Sa | 医薬製剤 |
JPH07316042A (ja) * | 1994-05-24 | 1995-12-05 | Shionogi & Co Ltd | マルチプルユニット型錠剤 |
JPH08175983A (ja) * | 1994-12-19 | 1996-07-09 | Taisho Yakuhin Kogyo Kk | ジクロフェナクナトリウム持続性製剤およびその製法 |
JPH09169645A (ja) * | 1995-12-20 | 1997-06-30 | Taisho Yakuhin Kogyo Kk | イブジラスト含有持続性製剤およびその製法 |
JPH10218761A (ja) * | 1997-02-07 | 1998-08-18 | Taisho Pharmaceut Co Ltd | マルチプルユニットタイプ徐放性錠剤 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124780B2 (en) | 2005-04-15 | 2012-02-28 | Eisai R&D Management Co., Ltd. | Benzimidazole compound |
WO2006118017A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 安定化組成物 |
AU2006242067B2 (en) * | 2005-04-28 | 2012-03-29 | Eisai R & D Management Co., Ltd. | Stabilized composition |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
Also Published As
Publication number | Publication date |
---|---|
HK1036220A1 (en) | 2001-12-28 |
AU746084B2 (en) | 2002-04-11 |
EP1072257A1 (en) | 2001-01-31 |
US6558700B1 (en) | 2003-05-06 |
CN1148171C (zh) | 2004-05-05 |
CN1294510A (zh) | 2001-05-09 |
CA2328154A1 (en) | 1999-10-28 |
KR20010034770A (ko) | 2001-04-25 |
AU8561798A (en) | 1999-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
WO1999053905A1 (fr) | Comprimes a liberation prolongee a unites multiples | |
US4828840A (en) | Sustained-release formulation and production thereof | |
JP2514078B2 (ja) | 圧縮成型製剤 | |
JP3015105B2 (ja) | 粉末被覆経口投与剤形 | |
JP2003508428A (ja) | 徐放される経口医薬投薬形 | |
WO1999016448A1 (fr) | Comprime de theophylline a liberation prolongee | |
US7138143B1 (en) | Coated preparation soluble in the lower digestive tract | |
JP2005512997A (ja) | タムスロシン錠 | |
IL177402A (en) | Composition for oral administration of tamsulosin hydrochloride | |
AU2003247409B2 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
HRP20010198A2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
JPS6248618A (ja) | 徐放性製剤およびその製造法 | |
WO1997033574A1 (fr) | Comprimes a liberation prolongee a base de valproate metallique | |
TW200914067A (en) | Sustained-release preparations and production process thereof | |
KR102419638B1 (ko) | 함량 균일성이 개선된 탐수로신 염산염 함유 서방성 펠렛을 포함하는 경구용 약제학적 제제 | |
JP3870470B2 (ja) | マルチプルユニットタイプ徐放性錠剤 | |
JPWO2002087549A1 (ja) | マルチプルユニット型徐放性錠剤 | |
CA2203222A1 (en) | Controlled-release pharmaceutical compositions | |
JP4367722B2 (ja) | マルチプルユニットタイプ徐放性錠剤 | |
JPS63267720A (ja) | エモルフアゾンの徐放性製剤 | |
JP4614139B2 (ja) | 塩酸タムスロシン徐放性錠剤の製造方法、およびそれからなる塩酸タムスロシン徐放性錠剤 | |
JPH02282323A (ja) | 徐放性錠剤の製造方法 | |
KR20050074767A (ko) | 염산 탐술로신의 경구 투여용 서방성 펠렛 조성물 및 그제조방법 | |
JPH0774166B2 (ja) | 徐放性被覆薬剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98814059.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007011272 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2328154 Country of ref document: CA Ref document number: 2328154 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09673398 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 85617/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998936707 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998936707 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007011272 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 85617/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007011272 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998936707 Country of ref document: EP |